Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Apr 08

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Apr 08

DOI: 10.23736/S1824-4785.21.03345-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology

Christoph WÜRNSCHIMMEL 1 , Mike WENZEL 2, Tobias MAURER 1, 3, Renato A. VALDÉS OLMOS 4, Sergi VIDAL-SICART 5, 6

1 Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 2 Department of Urology, University Hospital Frankfurt, Frankfurt, Germany; 3 Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; 4 Department of Radiology, Section of Nuclear Medicine & Interventional Molecular Imaging Laboratory, Leiden University Medical Center, Leiden, The Netherlands; 5 Nuclear Medicine Department, Hospital Clinic Barcelona, Barcelona, Spain; 6 Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain


PDF


Recent technical advances and implementation of novel radiotracers have further increased the potential of radioguided surgery for a broad variety of malignancies. Indeed, the possibilities for future applications of novel radiotracers in diverse oncological strategies has become more promising than ever. This literature review aims to provide a contemporary update on a selected group of radiotracers and evaluates the usability of radioguided surgery and sentinel node procedures, focusing on most promising advances. For example, the impact of targeted radiotracers on prostate specific membrane antigen (PSMA), CD206 receptor-targeted agents (99mTc-tilmanocept), and hybrid tracers adding fluorescence to radioguidance (ICG-99mTc-nanocolloid) as well as targeting hypoxiainduced carbonic anhydrase IX (CAIX) will be covered. Furthermore, future outlooks on the implementation of gold nanoparticles (AuNP’s), but also technical advances in improved radiotracer detection by hybrid gamma devices will be discussed.


KEY WORDS: Novel radiotracers; Radioguided surgery; Oncology

top of page